Sildenafil ameliorates cognitive deficits and tau pathology in a senescence-accelerated mouse model

Neurobiology of Aging

Volumn 33, Issue 3, 2012, Pages 625.e11-625.e20

  Orejana, Lourdes ^a   Barros Miñones, Lucía ^a   Jordán, Joaquín ^b   Puerta, Elena ^a   Aguirre, Norberto ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

Author keywords

Aging; Akt; Cyclin dependent kinase 5 (Cdk5); Glycogen synthase kinase 3 (GSK 3 ); SAMP8; Senescence accelerated; Sildenafil; Tau

Indexed keywords

CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN KINASE B; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVITY; HIPPOCAMPUS; LEARNING; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENESCENCE ACCELERATED MOUSE; SPATIAL MEMORY; TAUOPATHY;

EID: 84855784511     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.03.018     Document Type: Article

References (67)

1. Ahlijanian M.K., Barrezueta N.X., Williams R.D., Jakowski A., Kowsz K.P., McCarthy S., Coskran T., Carlo A., Seymour P.A., Burkhadt J.E., Nelson R.B., McNeish J.D. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2910-2915.
2. Alonso A., Zaidi T., Novac M., Grundke-Iqbal I., Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6923-6928.
3. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42:631-639.
4. Ashe K.H., Zahs K.R. Probing the biology of Alzheimer's disease in mice. Neuron 2010, 66:631-645.
5. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002, 103:26-35.
6. Avila J., Lucas J.J., Perez M., Hernandez F. Role of Tau protein in both physiological and pathological conditions. Physiol. Rev 2004, 84:361-384.
7. Bancher C., Braak H., Fischer P., Jellinger K.A. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci. Lett 1993, 162:179-182.
8. Baratti C.M., Boccia M.M. Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice. Behav. Pharmacol 1999, 10:731-737.
9. Barzilai N., Atzmon G., Derby C.A., Bauman J.M., Lipton R.B. A genotype of exceptional longevity is associated with preservation of cognitive function. Neurology 2006, 67:2170-2175.
10. Berger Z., Roder H., Hanna A., Carlson A., Rangachari V., Yue M., Wszolek Z., Ashe K., Knight J., Dickson D., Andorfer C., Rosenberry T.L., Lewis J., Hutton M., Janus C. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J. Neurosci 2007, 27:3650-3662.
11. Butterfield D.A., Howard B.J., Yatin S., Allen K.L., Carney J.M. Free radical oxidation of brain proteins in accelerated senescence and its modulation by N-tert-butyl-alpha-phenylnitrone. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:674-678.
12. Canudas A.M., Gutierrez-Cuesta J., Rodríguez M.I., Acuña-Castroviejo D., Sureda F.X., Camins A., Pallàs M. Hyperphosphorylation of microtubule-associated protein tau in senescence-accelerated mouse (SAM). Mech. Ageing Dev. 2005, 126:1300-1304.
13. Corcoran N.M., Martin D., Hutter-Paier B., Windisch M., Nguyen T., Nheu L., Sundstrom L.E., Costello A.J., Hovens C.M. Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. J. Clin. Neurosci 2010, 17:1025-1033.
14. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
15. Dahavan R., Tsai L.H. A decade of CDK5. Nat. Rev. Mol. Cell Biol 2001, 2:749-759.
16. Del Valle J., Duran-Vilaregut J., Manich G., Casadesús G., Smith M.A., Camins A., Pallàs M., Pelegrí C., Vilaplana J. Early amyloid accumulation in the hippocampus of SAMP8 mice. J. Alzheimers Dis. 2010, 19:1303-1315.
17. Delacourte A. The natural and molecular history of Alzheimer's disease. J. Alzheimers Dis 2006, 9:187-194.
18. Devan B.D., Bowker J.L., Duffy K.B., Bharati I.S., Jimenez M., Sierra-Mercado D., Nelson C.M., Spangler E.L., Ingram D.K. Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition. Psychopharmacology (Berl.) 2006, 183:439-445.
19. Devan B.D., Pistell P.J., Daffin L.W., Nelson C.M., Duffy K.B., Bowker J.L., Bharati I.S., Sierra-Mercado D., Spangler E.L., Ingram D.K. Sildenafil citrate attenuates a complex maze impairment induced by intracerebroventricular infusion of the NOS inhibitor Nomega-nitro-L-arginine methyl ester. Eur. J. Pharmacol 2007, 563:134-140.
20. Devan B.D., Sierra-Mercado D., Jimenez M., Bowker J.L., Duffy K.B., Spangler E.L., Ingram D.K. Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacol. Biochem. Behav 2004, 79:691-699.
21. Ding G., Jiang Q., Li L., Zhang L., Zhang Z.G., Ledbetter K.A., Panda S., Davarani S.P., Athiraman H., Li Q., Ewing J.R., Chopp M. Magnetic resonance imaging investigation of axonal remodeling and angiogenesis after embolic stroke in sildenafil-treated rats. J. Cereb. Blood Flow Metab 2008, 28:1440-1448.
22. Farr S.A., Poon H.F., Dogrukol-Ak D., Drake J., Banks W.A., Eyerman E., Butterfield D.A., Morley J.E. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J. Neurochem 2003, 84:1173-1183.
23. García-Matas S., Gutierrez-Cuesta J., Coto-Montes A., Rubio-Acero R., Díez-Vives C., Camins A., Pallàs M., Sanfeliu C., Cristòfol R. Dysfunction of astrocytes in senescence-accelerated mice SAMP8 reduces their neuroprotective capacity. Aging Cell 2008, 7:630-640.
24. Gerlai R. Behavioral tests of hippocampal function: simple paradigms complex problems. Behav. Brain Res 2001, 125:269-277.
25. Goñi-Allo B., Puerta E., Ramos M., Lasheras B., Jordán J., Aguirre N. Minoxidil prevents 3,4-methylenedioxymethamphetamine-induced serotonin depletions: role of mitochondrial ATP-sensitive potassium channels, Akt and ERK. J. Neurochem. 2008, 104:914-925.
26. Green K.N., Steffan J.S., Martinez-Coria H., Sun X., Schreiber S.S., Thompson L.M., LaFerla F.M. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phospho tau. J. Neurosci 2008, 5:11500-11510.
27. Guillozet A.L., Weintraub S., Mash D.C., Mesulam M.M. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch. Neurol 2003, 60:729-736.
28. Hamamoto H., Honma A., Irino M., Matsushita T., Toda K., Matsumura M., Takeda T. Grading score system: A method for evaluation of the degree of senescence in senescence accelerated mouse (SAM). Mech. Ageing Dev 1984, 26:91-102.
29. Hamdane M., Sambo A.V., Delobel P., Bégard S., Violleau A., Delacourte A., Bertrand P., Benavides J., Buée L. Mitotic-like tau phosphorylation by p25-Cdk5 kinase complex. J. Biol. Chem. 2003, 278:34026-34034.
30. Kumar V.B., Farr S.A., Flood J.F., Kamlesh V., Franko M., Banks W.A., Morley J.E. Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides 2000, 21:1769-1775.
31. Kusakawa G., Saito T., Ohuki R., Ishiguro K., Kishimoto T., Hisanaga S. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J. Biol. Chem 2000, 275:17166-17172.
32. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci 2001, 24:1121-1159.
33. Liu W., Liu C., Zhu J., Shu P., Yin B., Gong Y., Qiang B., Yuan J., Peng X. MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer's-associated pathogenesis in SAMP8 mice. Neurobiol. Aging 2010, Epub ahead of print. 10.1016/j.neurobiolaging.2010.04.034.
34. Maccioni R.B., Cambiazo V. Role of microtubule-associated proteins in the control of microtubule assembly. Physiol. Rev 1995, 75:835-864.
35. Mehta P.D. Amyloid beta protein as a marker or risk factor of Alzheimer's disease. Curr. Alzheimer Res 2007, 4:359-363.
36. Morley J.E., Farr S.A., Flood J.F. Antibody to amyloid beta protein alleviates impaired acquisition, retention, and memory processing in SAMP8 mice. Neurobiol. Learn. Mem 2002, 78:125-138.
37. Morley J.E., Kumar V.B., Bernardo A.E., Farr S.A., Uezu K., Tumosa N., Flood J.F. Beta-amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides 2000, 21:1761-1767.
38. Mostafa T. Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses. J. Sex. Med 2008, 5:2502-2518.
39. Nath R., Davis M., Probert A.W., Kupina N.C., Ren X., Schielke G.P., Wang K.K. Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. Biochem. Biophys. Res. Commun 2000, 274:16-21.
40. Okatani Y., Wakatsuki A., Reiter R.J., Miyahara Y. Melatonin reduces oxidative damage of neural lipids and proteins in senescence-accelerated mouse. Neurobiol. Aging 2002, 23:639-644.
41. Pallas M., Camins A., Smith M.A., Perry G., Lee H.G., Casadesus G. From aging to Alzheimer's disease: unveiling "the switch" with the senescence-accelerated mouse model (SAMP8). J. Alzheimers Dis 2008, 15:615-624.
42. Patil C.S., Singh V.P., Kulkarni S.K. Modulatory effect of sildenafil in diabetes and electroconvulsive shock-induced cognitive dysfunction in rats. Pharmacol. Rep 2006, 58:373-380.
43. Patrick G.N., Zukerberg L., Nikolic M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402:615-622.
44. Plattner F., Angelo M., Giese K.P. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem 2006, 281:25457-25465.
45. Poon H.F., Farr S.A., Thongboonkerd V., Lynn B.C., Banks W.A., Morley J.E., Klein J.B., Butterfield D.A. Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neurodegenerative disorders. Neurochem. Int 2005, 46:159-168.
46. Poon H.F., Joshi G., Sultana R., Farr S.A., Banks W.A., Morley J.E., Calabrese V., Butterfield D.A. Antisense directed at the Abeta region of APP decreases brain oxidative markers in aged senescence accelerated mice. Brain Res. 2004, 1018:86-96.
47. Prickaerts J., de Vente J., Honig W., Steinbusch H.W., Blokland A. cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation. Eur. J. Pharmacol 2002, 436:83-87.
48. Puerta E., Hervias I., Barros-Miñones L., Jordan J., Ricobaraza A., Cuadrado-Tejedor M., García-Osta A., Aguirre N. Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiol. Dis. 2010, 38:237-245.
49. Puerta E., Hervias I., Goñi-Allo B., Lasheras B., Jordan J., Aguirre N. Phosphodiesterase 5 inhibitors prevent 3,4-methylenedioxymethamphetamine-induced 5-HT deficits in the rat. J. Neurochem. 2009, 108:755-766.
50. Puzzo D., Staniszewski A., Deng S.X., Privitera L., Leznik E., Liu S., Zhang H., Feng Y., Palmeri A., Landry D.W., Arancio O. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. J. Neurosci 2009, 29:8075-8086.
51. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22:659-661.
52. Ricobaraza A., Cuadrado-Tejedor M., Pérez-Mediavilla A., Frechilla D., Del Río J., García-Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 2009, 34:1721-1732.
53. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
54. Rutten K., Vente J.D., Sik A., Ittersum M.M., Prickaerts J., Blokland A. The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices. Behav. Brain Res 2005, 164:11-16.
55. Sato S., Tatebayashi Y., Akagi T., Chui D.H., Murayama M., Miyasaka T., Planel E., Tanemura K., Sun X., Hashikawa T., Yoshioka K., Ishiguro K., Takashima A. Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells. J. Biol. Chem 2002, 277:42060-42065.
56. Shi Y.Q., Huang T.W., Chen L.M., Pan X.D., Zhang J., Zhu Y.G., Chen X.C. Ginsenoside Rg1 attenuates amyloid-beta content, regulates PKA/CREB activity, and improves cognitive performance in SAMP8 mice. J. Alzheimers Dis 2010, 19:977-989.
57. Sureda F.X., Gutierrez-Cuesta J., Romeu M., Mulero M., Canudas A.M., Camins A., Mallol J., Pallàs M. Changes in oxidative stress parameters and neurodegeneration markers in the brain of the senescence-accelerated mice SAMP-8. Exp. Gerontol. 2006, 41:360-367.
58. Tajes M., Gutierrez-Cuesta J., Folch J., Ortuño-Sahagun D., Verdaguer E., Jiménez A., Junyent F., Lau A., Camins A., Pallàs M. Neuroprotective role of intermittent fasting in senescence-accelerated mice P8 (SAMP8). Exp. Gerontol. 2010, 45:702-710.
59. Takashima A., Murayama M., Yazutake K., Takahashi H., Yokoyama M., Ishiguro K. Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain. Neurosci. Lett 2001, 306:37-40.
60. Takeda T. Senescence-accelerated mouse (SAM): a biogerontological resource in aging research. Neurobiol. Aging 1999, 20:105-110.
61. Takeda T., Hosokawa M., Higuchi K. Senescence accelerated mouse (SAM), a novel murine model of aging. The SAM Model of Senescence 1994, 15-22. Elsevier, Amsterdam. T. Takeda (Ed.).
62. Takeda T., Hosokawa M., Takeshita S., Irino M., Higuchi K., Matsushita T., Tomita Y., Yasuhira K., Hamamoto H., Shimizu K., Ishii M., Yamamuro T. A new murine model of accelerated senescence. Mech. Ageing Dev 1981, 17:183-194.
63. Timmer N.M., van Dijk L., van der Zee C.E., Kiliaan A., de Waal R.M., Verbeek M.M. Enoxaparin treatment administered at both early and late stages of amyloid beta deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain A beta levels. Neurobiol. Dis 2010, 40:340-347.
64. Tomobe K., Nomura Y. Neurochemistry, neuropathology, and heredity in SAMP8: a mouse model of senescence. Neurochem. Res 2009, 34:660-669.
65. Wang L., Gang Zhang Z., Lan Zhang R., Chopp M. Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J. Cereb. Blood Flow Metab 2005, 25:1150-1158.
66. Yasui F., Matsugo S., Ishibashi M., Kajita T., Ezashi Y., Oomura Y., Kojo S., Sasaki K. Effects of chronic acetyl-L-carnitine treatment on brain lipid hydroperoxide level and passive avoidance learning in senescence-accelerated mice. Neurosci. Lett 2002, 334:177-180.
67. Zhang L., Zhang R.L., Wang Y., Zhang C., Zhang Z.G., Meng H., Chopp M. Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Stroke 2005, 36:847-852.